Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Acadia Pharmaceuticals Inc shares valued at $148,720 were sold by Schneyer Mark C. on Aug 19 ’24. At $15.28 per share, Schneyer Mark C. sold 9,733 shares. The insider’s holdings dropped to 43,735 shares worth approximately $0.68 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Teehan Brendan sold 9,534 shares, netting a total of over 145,680 in proceeds. Following the sale of shares at $15.28 each, the insider now holds 52,177 shares.
Before that, DAVIS STEPHEN had sold 31,747 shares from its account. In a trade valued at $485,094, the CEO traded Acadia Pharmaceuticals Inc shares for $15.28 each. Upon closing the transaction, the insider’s holdings decreased to 31,747 shares, worth approximately $2.89 million.
As published in a research note from Morgan Stanley on August 07, 2024, Acadia Pharmaceuticals Inc [ACAD] has been rated down from an Overweight to an Equal-weight and the price target has been revised to $20 from $28. Analysts at BMO Capital Markets started covering the stock with ‘”an Outperform”‘ outlook in a report released in late June. As of March 12, 2024, Needham has reiterated its “Buy” rating for ACAD. Earlier on March 12, 2024, Mizuho downgraded its rating. Their new recommendation was “a Neutral” for ACAD stock which previously was a “a Buy”.
Analyzing ACAD Stock Performance
During the last five days, there has been a drop of approximately -5.72%. Over the course of the year, Acadia Pharmaceuticals Inc shares have dropped approximately -50.56%. Shares of the company reached a 52-week high of $31.82 on 01/02/24 and a 52-week low of $14.55 on 06/10/24. A 50-day SMA is recorded $16.64, while a 200-day SMA reached $19.83. Nevertheless, trading volume fell to 2.94 million shares from 3.9 million shares the previous day.
Support And Resistance Levels for Acadia Pharmaceuticals Inc (ACAD)
According to the 24-hour chart, there is a support level at 15.31, which, if violated, would cause prices to drop to 15.14. In the upper region, resistance lies at 15.65. The next price resistance is at 15.82. RSI (Relative Strength Index) is 40.89 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.47, which suggests the price will decrease in the coming days. Percent R is at 84.71%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
